🎉 M&A multiples are live!
Check it out!

Immutep Valuation Multiples

Discover revenue and EBITDA valuation multiples for Immutep and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

Immutep Overview

About Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.


Founded

1987

HQ

Australia
Employees

44

Website

immutep.com

Financials

LTM Revenue $3.3M

LTM EBITDA -$34.2M

EV

$163M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Immutep Financials

Immutep has a last 12-month revenue of $3.3M and a last 12-month EBITDA of -$34.2M.

In the most recent fiscal year, Immutep achieved revenue of n/a and an EBITDA of -$27.0M.

Immutep expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Immutep valuation multiples based on analyst estimates

Immutep P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$25.2M -$27.0M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$20.4M -$25.2M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Immutep Stock Performance

As of March 14, 2025, Immutep's stock price is AUD 0 (or $0).

Immutep has current market cap of AUD 415M (or $262M), and EV of AUD 257M (or $163M).

See Immutep trading valuation data

Immutep Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$163M $262M XXX XXX XXX XXX $-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Immutep Valuation Multiples

As of March 14, 2025, Immutep has market cap of $262M and EV of $163M.

Immutep's trades at 48.6x LTM EV/Revenue multiple, and -4.8x LTM EBITDA.

Analysts estimate Immutep's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Immutep and 10K+ public comps

Immutep Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $163M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -5.1x XXX XXX XXX
P/E -8.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -5.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Immutep Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Immutep Valuation Multiples

Immutep's NTM/LTM revenue growth is -17%

Immutep's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Immutep's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Immutep's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Immutep and other 10K+ public comps

Immutep Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 7% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Immutep Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Immutep M&A and Investment Activity

Immutep acquired  XXX companies to date.

Last acquisition by Immutep was  XXXXXXXX, XXXXX XXXXX XXXXXX . Immutep acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Immutep

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Immutep

When was Immutep founded? Immutep was founded in 1987.
Where is Immutep headquartered? Immutep is headquartered in Australia.
How many employees does Immutep have? As of today, Immutep has 44 employees.
Who is the CEO of Immutep? Immutep's CEO is Mr. Marc Voigt.
Is Immutep publicy listed? Yes, Immutep is a public company listed on ASX.
What is the stock symbol of Immutep? Immutep trades under IMM ticker.
When did Immutep go public? Immutep went public in 1988.
Who are competitors of Immutep? Similar companies to Immutep include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Immutep? Immutep's current market cap is $262M
What is the current revenue of Immutep? Immutep's last 12-month revenue is $3.3M.
What is the current EBITDA of Immutep? Immutep's last 12-month EBITDA is -$34.2M.
What is the current EV/Revenue multiple of Immutep? Current revenue multiple of Immutep is 48.6x.
What is the current EV/EBITDA multiple of Immutep? Current EBITDA multiple of Immutep is -4.8x.
Is Immutep profitable? Yes, Immutep is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.